### Comment:
What is your perspective on the paper? What do you see the optimal situation being?

### REPLY:
Boys, we don't use SGLT2 inhibitors in T1DM because of the high risk of DKA. So now we have a dual inhibitor. SGLT2 reabsorbs 90% of glucose from urine while SGLT1 takes care of the other 10%. Now we're inhibiting 100% of glucose reuptake (potentially). So tell me how the side effects arent just going to be more amplified and harmful. I wanna buy the calls but my clinical experience says no way.

### END.